Immutep enters into Strategic Collaboration with Dr. Reddy's
Filed with ASX · · 3 pages · English
• Under the terms, Immutep to receive upfront payment of USD 20 million (~AUD 30.2 million) and is also eligible to receive potential regulatory development and commercial milestone payments of up to USD 349.5 million (~AUD 528.4 million), plus double-digit royalties on commercial sales Sydney, Australia/Hyderabad, India-December 08, 2025 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “t
Earlier from Immutep
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
- New data presentation from AIPAC-003 Phase II for SABCS
- Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
- EFTISARC-NEO Phase II results presented at CTOS 2025
- Immutep Receives A$4.6 million R&D Tax Incentive from French Government
Later from Immutep
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- Positive Update on IMP761 Phase 1
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep